Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00545766 · ClinicalTrials.gov registry record · Phase 2
Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT00545766 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 41 participants.
The verdict
NCT00545766, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
Currently, there are no established 2nd-line or salvage chemotherapy regimens for patients with HRPC, many of whom retain an excellent performance status. The antitumor characteristics and toxicity profile of vinflunine make it an ideal agent to be investigated in this setting. In this Phase II trial, we plan to evaluate the efficacy, toxicity, and feasibility of administering IV vinflunine at a dose of 320 mg/m2 q3w as salvage chemotherapy in patients with HRPC. The patients will be evaluated for response, survival, and toxicity. If significant antitumor activity is demonstrated, further evaluation of this agent either alone or combination regimens and at earlier stages of disease will be indicated.
Interventions
- DRUG Vinflunine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-05 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00545766
The ClinicalTrials.gov registry entry for NCT00545766 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vinflunine is the first listed.
NCT00545766 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00545766 about?
NCT00545766 is a clinical study titled "Vinflunine in Hormone Refractory Prostate Cancer (HRPC)". Currently, there are no established 2nd-line or salvage chemotherapy regimens for patients with HRPC, many of whom retain an excellent performance status. The antitumor characteristics and toxicity profile of vinflunine make it an ideal agent to be investigated in this setting. In this Phase II tria...
What is the current status of trial NCT00545766?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2007-05. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00545766?
The interventions under investigation include: Vinflunine (DRUG).
Who is sponsoring clinical trial NCT00545766?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.